Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 5;29(12):1990-1992.
doi: 10.1093/ibd/izad030.

Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows

Badr Al-Bawardy  1   2 , Lisa Malter  3 , Adam C Ehrlich  4 , Florian Rieder  5 , Jill K J Gaidos  1 , Deborah Proctor  1 , Donna M Windish  6
Affiliations

Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows

Badr Al-Bawardy et al. Inflamm Bowel Dis. .
No abstract available

Keywords: education; inflammatory bowel disease; training.

Plain language summary

In this multicenter survey study, we found that many gastroenterology fellows lacked confidence and desired a “moderate to a lot more” training in important inflammatory bowel disease management domains.

PubMed Disclaimer

Conflict of interest statement

B.A-B.: Speaker honoraria from AbbVie, Takeda, Bristol-Meyers Squibb. Advisory board for Bristol-Meyers Squibb. Medical education grant from Takeda

L.M.: Medical education grants from AbbVie, Janssen, Pfizer, Takeda. Advisory board for AbbVie, Bristol-Meyers Squibb, Janssen, Merck, and Takeda.

A.C.D: Advisory boards for Pfizer, BMS, and Eli Lilly.

F.L.: consultant to Agomab, Allergan, AbbVie, Boehringer-Ingelheim, Celgene, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Metacrine, Morphic, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Takeda, Techlab, Thetis, UCB, and 89Bio.

J.K.J.G.: Speaker honoraria from AbbVie. Advisory Board for Bristol-Myers Squibb

D.P.: Consultant for AbbVie, Celgene, Paraxel

D.M.W.: none.

Figures

Figure 1.
Figure 1.
GI fellows’ level of confidence across 20 core IBD domains.
Figure 2.
Figure 2.
Low confidence among third-year vs. first- and second-year GI fellows.
See this image and copyright information in PMC

References

    1. Cohen BL, Ha C, Ananthakrishnan AN, Rieder F, Bewtra M. State of adult trainee inflammatory bowel disease education in the united states: a national survey. Inflamm Bowel Dis. 2016;22(7):1609-1615. - PMC - PubMed
    1. Al-Bawardy B, Shivashankar R, Proctor DD. Novel and emerging therapies for inflammatory bowel disease. Front Pharmacol. 2021;12:651415. - PMC - PubMed
    1. Sands BE, Sandborn WJ, Panaccione R, et al. ; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. - PubMed
    1. Sandborn WJ, Su C, Sands BE, et al. ; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736. - PubMed
    1. Sandborn WJ, Feagan BG, D'Haens G, et al. ; True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291. - PubMed